TrialBritish journal of cancer2014

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours.

I Brana et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.